Involvement of the amygdala on place aversion induced by naloxone in single-dose morphine-treated rats

Yakugaku Zasshi

Volumn 128, Issue 3, 2008, Pages 395-403

  Ishida, Shigeru ^a   Shimosaka, Riho ^a   Kawasaki, Yoichi ^b   Jin, Chunyu ^a   Kitamura, Yoshihisa ^a   Araki, Hiroaki ^c   Sendo, Toshiaki ^a,b   Gomita, Yutaka ^a,b  

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^c EHIME UNIVERSITY HOSPITAL   (Japan)

Author keywords

Acute dependence; Central amygdaloid nucleus (CeA); Conditioned place aversion; Glutamatergic neurotransmission; Morphine; Naloxone

Indexed keywords

1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; ALPHA METHYL 4 CARBOXYPHENYLGLYCINE; AMPA RECEPTOR ANTAGONIST; DIZOCILPINE; GLUTAMATE RECEPTOR ANTAGONIST; METABOTROPIC RECEPTOR ANTAGONIST; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NALOXONE; OPIATE ANTAGONIST; PROTEIN C FOS; RILUZOLE;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; AVERSION; CONTROLLED STUDY; MORPHINE ADDICTION; NERVE PROJECTION; NEUROTRANSMISSION; NONHUMAN; NUCLEUS ACCUMBENS; OPIATE ADDICTION; PLACE PREFERENCE; PROTEIN EXPRESSION; RAT; REVIEW; WITHDRAWAL SYNDROME;

AMYGDALA; ANIMALS; BEHAVIOR, ANIMAL; CONDITIONING (PSYCHOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTAMATES; HUMANS; MORPHINE; MORPHINE DEPENDENCE; NALOXONE; NEUROTRANSMITTER AGENTS; PROTO-ONCOGENE PROTEINS C-FOS; RATS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 40449114730     PISSN: 00316903     EISSN: 13475231     Source Type: Journal    
DOI: 10.1248/yakushi.128.395     Document Type: Review

References (54)

1. Bickel W. K., Stitzer M. L., Liebson I. A., Bigelow G. E., J. Pharmacol. Exp. Ther., 244, 126-132 (1988).
2. Heishman S. J., Stitzer M. L., Bigelow G. E., Liebson I. A., Pharmacol. Biochem. Behav., 36, 393-399 (1990).
3. June H. L., Stitzer M. L., Cone E., Clin. Pharmacol. Ther., 57, 270-280 (1995).
4. Easterling K. W., Holtzman S. G., J. Pharmacol. Exp. Ther., 281, 188-199 (1997).
5. Parker L. A., Cyr J. A., Santi A. N., Burton P. D., Pharmacol. Biochem. Behav., 72, 87-92 (2002).
6. Martin W. R., Eades C. G., J. Pharmacol. Exp. Ther., 146, 385-394 (1964).
7. Ramabadran K., Life Sci., Suppl 1, 385-388 (1983).
8. Schulteis G., Heyser C. J., Koob G. F., Psychopharmacology (Berlin), 129, 56-65 (1997).
9. Gellert V. F., Sparber S. B., J. Pharmacol. Exp. Ther., 201, 44-54 (1977).
10. McDonald R. V., Parker L. A., Siegel S., Pharmacol. Biochem. Behav., 58, 1003-1008 (1997).
11. Parker L. A., Joshi A., Pharmacol. Biochem. Behav., 61, 331-333 (1998).
12. Herman B. H., Vocci F., Bridge P., Neuropsychopharmacology, 13, 269-293 (1995).
13. Trujillo K. A., Akil H., Science, 251, 85-87 (1991).
14. Watanabe T., Nakagawa T., Yamamoto R., Maeda A., Minami M., Satoh M., Jpn. J. Pharmacol., 88, 399-406 (2002).
15. Haertzen C. A., Hooks N. T., J. Nerv. Ment. Dis., 148, 606-614 (1969).
16. Henningfield J. E., Johnson R. E., Jasinski D. R., "Methods of Assessing the Reinforcing Properties of abused Drugs," Chap. 27, ed. by Bozarth M. A., Springer-Verlag, New York, 1987, pp. 573-590.
17. Jaffe J.H., "Goodman and Gilman's The Pharmacological Basis of Therapeutics," 8th edition, Chap. 22, eds. by Gilman A. G., Rall T.W., Nies A. S., Taylor P., Pergamon Press, New York, 1990, pp. 522-573.
18. Higgins G. A., Sellers E. M., Pharmacol. Biochem. Behav., 48, 1-8 (1994).
19. Schulteis G., Markou A., Gold L. H., Stinus L., Koob G. F., J. Pharmacol. Exp. Ther., 271, 1391-1398 (1994).
20. Azar M. R., Jones B. C., Schulteis G., Psychopharmacology (Berlin), 170, 42-50 (2003).
21. Parker L. A., Rennie M., Pharmacol. Biochem. Behav., 41, 559-565 (1992).
22. Araki H., Kawakami K., Jin C., Suemaru K., Kitamura Y., Nagata M., Futagami K., Shibata K., Kawasaki H., Gomita Y., Psychopharmacology (Berlin), 171, 398-404 (2004).
23. Alheid G. F., Heimer L., Neuroscience, 27, 1-39 (1988).
24. Alheid G. F., de Olmos J. S., Beltramino C. A., "The Rat Nervous System," 2nd edition, Chap. 22, ed. by Paxinos G., Academic Press, San Diego, 1995, pp. 495-578.
25. de Olmos J. S., Heimer L., Ann. N. Y. Acad. Sci., 877, 1-32 (1999).
26. Stinus L., Le Moal M., Koob G. F., Neuroscience, 37, 767-773 (1990).
27. Kelsey J. E., Arnold S. R., Behav. Neurosci., 108, 1119-1127 (1994).
28. Heinrichs S. C., Menzaghi F., Schulteis G., Koob G. F., Stinus L., Behav. Pharmacol., 6, 74-80 (1995).
29. Delfs J. M., Zhu Y., Druhan J. P., Aston-Jones G., Nature, 403, 430-434 (2000).
30. Gracy K. N., Dankiewicz L. A., Koob G. F., Neuropsychopharmacology, 24, 152-160 (2001).
31. Jin C., Araki H., Nagata M., Suemaru K., Shibata K., Kawasaki H., Hamamura T., Gomita Y., Psychopharmacology (Berlin), 175, 428-435 (2004).
32. Jin C., Araki H., Nagata M., Shimosaka R., Shibata K., Suemaru K., Kawasaki H., Gomita Y., Behav. Brain Res., 161, 107-112 (2005).
33. Schulteis G., Stinus L., Risbrough V. B., Koob G. F., Neuropsychopharmacology, 19, 406-416 (1998).
34. Beninger R. J., Herz R. S., Life Sci., 38, 1425-1431 (1986).
35. Horvitz J. C., Ettenberg A., Behav. Neurosci., 105, 536-541 (1991).
36. Harris G. C., Aston-Jones G., Neuropsychopharmacology, 28, 292-299 (2003).
37. Tzschentke T. M., Schmidt W. J., Mol. Psychiatry, 8, 373-382 (2003).
38. Aghajanian G. K., Kogan J. H., Moghaddam B., Brain Res., 636, 126-130 (1994).
39. Tokuyama S., Zhu H., Oh S., Ho I. K., Yamamoto T., Neurochem. Int., 39, 103-109 (2001).
40. Sepulveda M. J., Hernandez L., Rada P., Tucci S., Contreras E., Pharmacol. Biochem. Behav., 60, 255-262 (1998).
41. Tokuyama S., Wakabayashi H., Ho I. K., Eur. J. Pharmacol., 295, 123-129 (1996).
42. Rasmussen K., Fuller R. W., Stockton M. E., Perry K. W., Swinford R. M., Ornstein P. L., Eur. J. Pharmacol., 197, 9-16 (1991).
43. Higgins G. A., Nguyen P., Sellers E. M., Life Sci., 50, PL167-172 (1992).
44. Cappendijk S. L., de Vries R., Dzoljic M. R., Eur. Neuropsychopharmacol., 3, 111-116 (1993).
45. Taylor J. R., Punch L. J., Elsworth J. D., Psychopharmacology (Berlin), 138, 133-142 (1998).
46. Sepulveda J., Astorga J. G., Contreras E., Eur. J. Pharmacol., 379, 59-62 (1999).
47. Vandergriff J., Rasmussen K., Neuropharmacology, 38, 217-222 (1999).
48. Rasmussen K., Vandergriff J., Neuropharmacology, 44, 88-92 (2003).
49. Popik P., Danysz W., J. Pharmacol. Exp. Ther., 280, 854-865 (1997).
50. Watanabe T., Yamamoto R., Maeda A., Nakagawa T., Minami M., Satoh M., Brain Res., 958, 423-428 (2002).
51. Nakagawa T., Yamamoto R., Fujio M., Suzuki Y., Minami M., Satoh M., Kaneko S., Neuroscience, 134, 9-19 (2005).
52. Popik P., Wrobel M., Neuropharmacology, 43, 1210-1217 (2002).
53. Biondo A. M., Clements R. L., Hayes D. J., Eshpeter B., Greenshaw A. J., Psychopharmacology (Berlin), 179, 189-197 (2005).
54. Kawasaki Y., Jin C., Suemaru K., Kawasaki H., Shibata K., Choshi T., Hibino S., Gomita Y., Araki H., Br. J. Pharmacol., 145, 751-757 (2005).